ESH AL 2020 | Treatment options for high-risk AML
Nigel Russell
• 16 Jun 2020
Nigel Russell, MD, Guy’s Hospital NHS Trust, London, UK, talks on attempts to improve treatment options for younger patients with high-risk acute myeloid leukemia (AML). Specifically discussed is the UK NCRI AML17 trial (ISRCTN55675535), comparing FLAG-Ida and daunorubicin with clofarabine for high-risk AML. Prof. Russell highlights the importance of early recognition of high-risk disease and reveals that optimizing induction and pre-stem cell transplant treatment allows more patients to get to transplant in remission. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
